Mice

BB Brigid S. Boland
ZH Zhaoren He
MT Matthew S. Tsai
JO Jocelyn G. Olvera
KO Kyla D. Omilusik
HD Han G. Duong
EK Eleanor S. Kim
AL Abigail E. Limary
WJ Wenhao Jin
JM J. Justin Milner
BY Bingfei Yu
SP Shefali A. Patel
TL Tiani L. Louis
TT Tiffani Tysl
NK Nadia S. Kurd
AB Alexandra Bortnick
LQ Lauren K. Quezada
JK Jad N. Kanbar
AM Ara Miralles
DH Danny Huylebroeck
MV Mark A. Valasek
PD Parambir S. Dulai
SS Siddharth Singh
LL Li-Fan Lu
JB Jack D. Bui
CM Cornelis Murre
WS William J. Sandborn
AG Ananda W. Goldrath
GY Gene W. Yeo
JC John T. Chang
request Request a Protocol
ask Ask a question
Favorite

All mice were housed under specific pathogen–free conditions in an American Association of Laboratory Animal Care–approved facility at UCSD, and all procedures were approved by the UCSD Institutional Animal Care and Use Committee. C57BLJ/6 CD45.1, CD45.2, CD45.1.2, P14 TCR transgenic (CD45.1 or CD45.1.2, both maintained on a C57BL6/J background), RAG1-deficient, and IL-10–deficient mice were bred at UCSD or purchased from the Jackson Laboratories. Mice with a loxP-flanked Zeb2 allele (35, 65) were bred with Rosa26Cre-ERT2 (ERCre) mice (66) and were maintained on a C57BL/J6 background. Rosa26Cre-ERT2–mediated deletion of the floxed Zeb2 gene was induced by oral gavage of 1 mg of tamoxifen (Cayman Chemical Company) emulsified in 100 μl of sunflower seed oil (Sigma-Aldrich) for five consecutive days and then rested for 5 days. Cells for Treg cell suppression assays were obtained from male mice that were 12 to 28 weeks old.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A